Moderna's mFlusiva mRNA Flu Vaccine Approved by US FDA FAST-MOVING
The U.S. Food and Drug Administration has granted approval to Moderna's mFlusiva, the first mRNA‑based seasonal influenza vaccine in the United States. The vaccine is authorized for adults aged 50 years and older. Full approval was given for the 50‑64 age group based on a phase‑3 trial of roughly 40,000 participants that showed about a 27 % reduction in laboratory‑confirmed flu cases compared with a standard‑dose vaccine. An accelerated approval was issued for adults 65 and older, relying on a smaller study that demonstrated a strong immune response relative to an existing high‑dose flu shot. Clinical data revealed no major safety concerns; the most common adverse events were mild‑to‑moderate injection‑site pain, fever, headache, fatigue and muscle aches. Moderna expects limited supplies to reach selected retailers before the 2026‑2027 flu season. The approval follows an earlier FDA refusal to review the application, a February decision by a senior FDA official that was later reversed, and a unanimous recommendation from an independent advisory committee in June. The agency’s decision was announced amid ongoing debate over mRNA technology, with Health Secretary Robert F. Kennedy Jr. previously criticizing the platform. European regulators are still reviewing the vaccine.
Entities: Food and Drug Administration (FDA) · Moderna · Moderna Inc. · Robert F. Kennedy Jr. · Stéphane Bancel · U.S. Food and Drug Administration · U.S. Food and Drug Administration (FDA) · mFLUSIVA · mFlusiva (mRNA‑1010)
Claims
What the coverage asserts, and how well corroborated each claim is across sources.
- [● 10 SOURCES] Moderna expects limited supplies of mFlusiva to be available at select retailers ahead of the 2026‑2027 flu season. (Moderna expects limited supplies to reach select retailers before the 2026‑2027 flu season.)
- [● 8 SOURCES] The approval followed earlier controversy, including a February decision by a senior FDA official to block the application, which was later reversed. (The approval followed a highly unusual public dispute … after a senior FDA official blocked the company’s application …)
- [● 13 SOURCES] The FDA approved Moderna's mFlusiva, the first mRNA-based seasonal influenza vaccine in the United States. (FDA approval of mFlusiva)
- [● 13 SOURCES] mFlusiva is indicated for adults aged 50 and older. (The vaccine is intended for adults age 50 and older.)
- [● 11 SOURCES] No major safety concerns were identified; the most common adverse events were mild‑to‑moderate injection‑site pain, fever, headache, fatigue and muscle aches. (The data reviewed so far revealed no major safety concerns, though recipients reported typical temporary reactions such)
- [● 13 SOURCES] An independent FDA advisory committee unanimously recommended approval in June after the agency initially declined to review the application. (The panel unanimously concluded that the vaccine’s benefits outweighed its risks … after the agency initially declined …)
- [● 9 SOURCES] Accelerated approval for adults 65+ was granted after a smaller study showed a strong immune response compared with an existing high‑dose flu vaccine. (For people 65 or older, the FDA granted accelerated approval … based on a smaller study showing a strong immune response)
- [● 9 SOURCES] Full approval for adults 50‑64 was based on a phase‑3 trial of about 40,000 participants that showed roughly a 27 % reduction in flu cases versus a standard vaccine. (Evidence Behind the ApprovalFor adults ages 50 to 64, regulators granted full approval after a trial involving 40,000 …)
- [● 3 SOURCES] The FDA approved Moderna's mFlusiva, the first mRNA flu vaccine in the United States. (The Food and Drug Administration has approved Moderna’s mFlusiva, the first U.S. influenza vaccine made with messenger‑R)